🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
ZNN Bactiguard Antegrade Femoral Nails PMCF Study
NCT05339360Femur Fracture, Osteotomy
Zimmer Biomet
Observational
100
Manchester
2024-01-16
Recruiting
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
NCT05970172Chronic Kidney Disease, Renal Anemia
Astellas Pharma Global Development, Inc.
Phase 3
100
Cardiff, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2024-01-16
Active, closed
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
NCT05818150Knee Osteoarthritis
Merit Medical Systems, Inc.
Not applicable
264
Bournemouth, Cwmbran
2024-01-16
Active, closed
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513Limb-girdle Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
17
Newcastle upon Tyne
2024-01-15
Recruiting
Registry of GORE® ACUSEAL Vascular Graft in Dialysis Access
NCT05846581Chronic Kidney Diseases, End Stage Renal Disease on Dialysis
W.L.Gore & Associates
Observational
72
Bristol
2024-01-12
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Birmingham, Cardiff, Glasgow, Hexham, London, Manchester
2024-01-11
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3
410
Aberdeen, London, Nottingham, Sutton, Torquay
2024-01-11
Recruiting
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
NCT06412250Cardiovascular Diseases
Translumina Therapeutics Pvt Ltd.
Observational
2,000
Bedford, Newcastle, Plymouth, Salisbury, Wigan
2024-01-10
Active, closed
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632Advanced or Metastatic Breast Cancer
Pfizer
Phase 2
333
London
2024-01-09
Recruiting
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06174987Advanced Cancer, Metastatic Cancer
Daiichi Sankyo
Phase 3
50
Guildford
2024-01-05
Active, closed
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390Post-Bariatric Hypoglycemia
RECORDATI GROUP
Phase 2
93
Bristol, London
2024-01-04
By invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315Wheezing, Asthma
Sanofi
Phase 3
90
Birmingham, Leicester, London, Bradford
2024-01-03
Active, closed
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281Hypophosphatasia
Alexion Pharmaceuticals, Inc.
Phase 3
124
London
2024-01-03
Active, closed
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT06280209Duchenne Muscular Dystrophy
BioMarin Pharmaceutical
Phase 1/2
18
London
2024-01-03
Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
Celcuity Inc
Phase 1/2
54
Cambridge, Southampton, Sutton
2024-01-01
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
Merck Sharp & Dohme LLC
Phase 3
1,310
Cambridge, Truro, Glasgow, London, Manchester
2023-12-31
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
Merck Sharp & Dohme LLC
Phase 3
340
Cambridge, Gloucester, Lincoln, Boston, London, Gwent, Windsor, Manchester
2023-12-31
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb
Phase 1/2
460
Southampton, Manchester, Edinburgh
2023-12-29
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
London, Manchester, Surrey
2023-12-29
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals
Phase 3
580
Truro, Plymouth, Bournemouth, Salisbury, Uxbridge, Sutton, Great Yarmouth, Romford
2023-12-28
Recruiting
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085Homocystinuria
Travere Therapeutics, Inc.
Phase 3
70
Birmingham, London, Salford
2023-12-28
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
London, Oxford, Southhampton
2023-12-27
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Recruiting
Affera Global Registry
NCT06026345Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
540
Cambridge, London
2023-12-22
Recruiting
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
NCT06645236Metastatic Colorectal Cancer (mCRC)
QIAGEN Gaithersburg, Inc
Not applicable
600
Manchester
2023-12-22
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
2023-12-21
Recruiting
IONA Longitudinal Cohort Study
NCT05892952Alzheimer Disease, Dementia
Brain Health Scotland Life Sciences Ltd
Observational
10,000
Edinburgh
2023-12-21
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Edgbaston, Cambridge, Reading
2023-12-20
Active, closed
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
Phase 3
200
London, Manchester, Nottingham
2023-12-20
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
Janssen Research & Development, LLC
Phase 1
300
London, Oxford
2023-12-20
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
London, Manchester, Salford
2023-12-20
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Recruiting
Danon Disease Natural History Study
NCT06214507Danon Disease
Rocket Pharmaceuticals Inc.
Observational
60
London
2023-12-20
Recruiting
Improving CRT Outcome With Non-Invasive Cardiac Mapping
NCT05564793Heart Failure With Reduced Ejection Fraction
EP Solutions SA
Not applicable
330
London, Oxford
2023-12-20
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
400
Birmingham, Bournemouth, Liverpool, London, Manchester, Stoke-on-Trent, Swansea, West Bromwich
2023-12-20
Recruiting
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
NCT06016920HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Nykode Therapeutics ASA
Phase 1/2
110
London
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,314
Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford
2023-12-18
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.
Observational
900
Birmingham, London, Wolverhampton
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Taiho Oncology, Inc.
Phase 3
285
London, Nottingham, Torquay
2023-12-18
Active, closed
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986Systemic Lupus Erythematosus
Hoffmann-La Roche
Phase 1
70
London
2023-12-18
Recruiting
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
NCT05789758Muscular Atrophy, Spinal
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
London, Portsmouth, Canterbury, Central Middlesbrough
2023-12-15
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
Glasgow, Leeds, London, Oxford
2023-12-13
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals
Phase 3
904
Aberdeen, Uxbridge
2023-12-13
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics
Phase 3
1,200
Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
2023-12-13
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Active, closed
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105GIST
Deciphera Pharmaceuticals, LLC
Phase 3
54
London, Leeds
2023-12-13
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Exeter, London, Inverness, Canterbury, Salford
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Active, closed
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
NCT06152237Rett Syndrome
Taysha Gene Therapies, Inc.
Phase 1/2
6
London
2023-12-12
Active, closed
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Generate Biomedicines
Phase 1
156
London, Manchester, Merthyr Tydfil
2023-12-12
Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254Follicular Lymphoma (FL)
Regeneron Pharmaceuticals
Phase 3
822
Truro, Plymouth, Bournemouth, Glasgow, Norwich, Romford
2023-12-12
Active, closed
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
NCT06149403MPS-IH (Hurler Syndrome)
Orchard Therapeutics
Phase 3
41
Manchester
2023-12-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Sheffield, London, Birmingham
2023-12-11
Active, closed
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals
Phase 2
145
Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham
2023-12-11
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
Sanofi
Phase 2
197
Cambridge, Dundee, Birmingham, Glasgow, Leicester, Harrow
2023-12-11
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Birmingham, Bristol, London, Sheffield
2023-12-08
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
London
2023-12-08
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
Novartis Pharmaceuticals
Phase 3
362
Oxford
2023-12-07
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Aura Biosciences
Phase 3
108
London, Sheffield
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
East Sussex, Derby, London, Truro, Glasgow, Manchester
2023-12-06
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca
Phase 1/2
564
Cambridge, Leeds, London, Manchester
2023-12-05
Active, closed
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972Ulcerative Colitis
Gilead Sciences
Phase 2
176
Bury, Cambridge, London, Norwich, Southampton
2023-12-05
Recruiting
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
NCT06246136Open Angle Glaucoma
Elios Vision, Inc.
Not applicable
194
East Grinstead, Edinburgh, Guildford, London, Manchester
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton
2023-12-04
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
AnaptysBio, Inc.
Phase 2
132
Belfast, Cambridge, Liverpool, London, Runcorn, Shrewsbury, York
2023-12-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
Akero Therapeutics, Inc
Phase 3
1,650
Birmingham, Cambridge, Liverpool, London, Newcastle upon Tyne
2023-12-01
Active, closed
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183Advanced Malignant Solid Tumor
BioNTech SE
Phase 1
41
London, Manchester, Newcastle
2023-11-30
Active, closed
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
13
London, Oxford
2023-11-29
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton
2023-11-29
Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
NCT06166056Bronchiectasis
Chiesi Farmaceutici S.p.A.
Phase 1/2
45
Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton
2023-11-29
Recruiting
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
NCT05935358Severe Hemophilia A
Octapharma
Phase 4
28
Leeds
2023-11-28
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471NonSegmental Vitiligo
Incyte Corporation
Phase 3
450
Ipswich, Leicester, London, Nottingham, Walsall
2023-11-27
Recruiting
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Alcyone Therapeutics, Inc
Not applicable
90
Sheffield
2023-11-27
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 1
127
Barnsley, Blackpool, Cambridge, Cannock, London, Manchester, West Yorkshire
2023-11-27
Recruiting
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947Hypochondroplasia
BioMarin Pharmaceutical
Observational
400
London, Glasgow
2023-11-27
Active, closed
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531Hyperphagia in Prader-Willi Syndrome
ACADIA Pharmaceuticals Inc.
Phase 3
170
Birmingham, Glasgow, London
2023-11-27
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Genentech, Inc.
Phase 1
65
Cambridge, Leicester, London, Oxford, Sutton
2023-11-27
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
Novartis Pharmaceuticals
Phase 2/3
232
London
2023-11-24
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Recruiting
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
NCT06844136Ovarian Cancer
Pierian Biosciences
Observational
100
Liverpool
2023-11-22
By invitation
Performance of REMS Bone Densitometry in a British Population
NCT06151353Bone Densitometry
OsteoscanUK Ltd
Observational
2,500
Daventry
2023-11-21
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
London, Edinburgh
2023-11-20
Recruiting
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Autolus Limited
Phase 1
30
London, Manchester, Newcastle upon Tyne
2023-11-16
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Nottingham, Sutton, Torquay, Truro
2023-11-16
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
High Wycombe, Cambridge, London, North Finchley, Birmingham, Dudley, Prescot, Stockport
2023-11-15
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
470
Birmingham
2023-11-15
By invitation
A Prospective Study of Fortiva in Hernia Repair
NCT06101979Ventral Hernia, Incisional Hernia, Abdominal Wall Reconstruction
RTI Surgical
Observational
120
Great Yarmouth
2023-11-15
Active, closed
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364Follicular Lymphoma (FL)
Regeneron Pharmaceuticals
Phase 3
733
Truro, Uxbridge, Birmingham, Aberdeen
2023-11-14
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Sutton, London
2023-11-14
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
Takeda
Phase 3
80
London, Manchester, Nottingham, Birmingham
2023-11-13
Recruiting
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
NCT06193902Tumor, Solid
Leucid Bio
Phase 1/2
17
London, Manchester
2023-11-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
556
London, Sutton, Manchester, Metropolitan Borough of Wirral
2023-11-12
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Active, closed
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571NASH/MASH, NAFLD/MASLD
Akero Therapeutics, Inc
Phase 3
700
Liverpool, London, Newcastle upon Tyne
2023-11-10
Recruiting
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729Pulmonary Sarcoidosis
Xentria, Inc.
Phase 1/2
94
Coventry, London, Norwich, Oxford, Perth
2023-11-10
Rows per page Showing 1401–1500 of 2847
Previous 13 14 15 16 17 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=15

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.